cells

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy details Category: DNA RNA and cells Posted on Saturday, January 28, 2023 at 6:33 pm Visit: 132 The START-001 study uses a tissue-agnostic biomarker-enriched approach to evaluate …

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells Read More »

A new technique could make fuel cells cheaper and more sustainable

In a study published in Science Advances, researchers from the Faculty of Chemistry at the University of New South Wales (UNSW) show that it is possible to sequentially ‘grow’ interconnected hierarchical structures in 3D at the nanoscale that have unique chemical and physical properties to support the energy conversion reaction. In chemistry, hierarchical structures are …

A new technique could make fuel cells cheaper and more sustainable Read More »

Pepromene Bio, Inc. announced a complete response in the first patient treated in the phase 1 B-cell non-Hodgkin’s lymphoma (B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) at City of Hope

IRVINE, California, December 20, 2022 /CNW/ — PeproMene Bio, Inc., a clinical biotechnology company developing novel therapies for the treatment of cancer and immune disorders, today announced that the first patient has been treated for stage 1 relapsed or refractory B-cell non-Hodgkin’s lymphoma (r /r B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) achieved a complete …

Pepromene Bio, Inc. announced a complete response in the first patient treated in the phase 1 B-cell non-Hodgkin’s lymphoma (B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) at City of Hope Read More »